intranasal route comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
To completely block the uptake of iodine-131 by the purposeful addition of perchlorate ions to a populace's water supply, aiming at dosages of 0.5 mg/kg-day, or a water concentration of 17 ppm, would therefore be grossly inadequate at truly reducing radioiodine uptake. Perchlorate ion concentrations in a region's water supply would need to be much higher, at least 7.15 mg/kg of body weight per day, or a water concentration of 250 ppm, assuming people drink 2 liters of water per day, to be truly beneficial to the population at preventing bioaccumulation when exposed to a radioiodine environment, independent of the availability of iodate or iodide drugs. The continual distribution of perchlorate tablets or the addition of perchlorate to the water supply would need to continue for no less than 80–90 days, beginning immediately after the initial release of radioiodine was detected. After 80–90 days passed, released radioactive iodine-131 would have decayed to less than 0.1% of its initial quantity, at which time the danger from biouptake of iodine-131 is essentially over. In the event of a radioiodine release, the ingestion of prophylaxis potassium iodide, if available, or even iodate, would rightly take precedence over perchlorate administration, and would be the first line of defense in protecting the population from a radioiodine release.
TRV250 is a δ-opioid receptor (DOR) agonist which is under development for the treatment of migraine. It is taken orally. The drug shows high selectivity for the DOR over the μ- and κ-opioid receptors. It is a biased agonist of the DOR, with preference for activation of G protein signaling over β-arrestin2 signaling. TRV250 produces analgesic, antimigraine-like, antidepressant-like, and anxiolytic-like effects in rodents. In addition, it has dramatically reduced proconvulsant activity relative to non-biased DOR agonists in rodents and monkeys, with a 50- to 80-fold margin between analgesia and seizures. TRV250 is being developed by Trevena. As of April 2025, the drug is in phase 2 clinical trials for treatment of migraine. No recent development has been reported for treatment of CNS disorders, while development for treatment of neuropathic pain and Parkinson's disease was discontinued. TRV250 was first described in the scientific literature in 2015.
==== Second Schleswig War ==== In 1863, conflict broke out again when Frederick VII died without legitimate issue. According to the order of succession of Denmark and Schleswig, the crowns of both Denmark and Schleswig would pass to Duke Christian of Glücksburg, who became Christian IX. The transmission of the duchy of Holstein to the head of the (German-oriented) branch of the Danish royal family, the House of Augustenborg, was more controversial. The separation of the two duchies was challenged by the Augustenborg heir, who claimed, as in 1848, to be the rightful heir of both Schleswig and Holstein. A common constitution for Denmark and Schleswig was promulgated in November 1863, which was a breach of the 1852 London Protocol. This left Denmark politically isolated and led to the Second Schleswig War, with Prussia and Austria invading once again. Denmark achieved some initial victories at the Battles of Mysunde, and Sankelmark, but these successes were short-lived. The Austrians defeated the Danes at the Königshügel and Vejle. However, it was the Prussians who decided the war by decisively winning the pivotal Battles of Dybbøl and Als. British attempts to mediate in the London Conference of 1864 failed. With the peace Treaty of Vienna (1864), Denmark was forced to cede Schleswig, Holstein, and Lauenburg to Prussia and Austria. Prussia wished to annex the conquered territories, but Austria insisted they be held as condominiums.
In the oil and gas industry, polyacrylamide derivatives (especially co-polymers) have a substantial effect on production by enhanced oil recovery by viscosity enhancement. High viscosity aqueous solutions can be generated with low concentrations of polyacrylamide polymers, which are injected to improve the economics of conventional water-flooding. In a separate application, hydraulic fracturing benefits from drag reduction resulting from injection of these solutions. These applications use large volumes of polymer solutions at concentration of 30–3000 mg/L.
=== Toxicity === TTX is extremely toxic. The material safety data sheet for TTX lists the oral median lethal dose (LD50) for mice as 334 μg per kg. For comparison, the oral LD50 of potassium cyanide for mice is 8,500 μg per kg, demonstrating that even orally, TTX is more poisonous than cyanide. TTX is even more dangerous if administered intravenously; the amount needed to reach a lethal dose by injection is 8 μg per kg in mice. The toxin can enter the body of a victim by ingestion, injection, or inhalation, or through abraded skin. Poisoning occurring as a consequence of consumption of fish from the order Tetraodontiformes is extremely serious. The organs (e.g., liver) of the pufferfish can contain levels of tetrodotoxin sufficient to produce the described paralysis of the diaphragm and corresponding death due to respiratory failure. Toxicity varies between species and at different seasons and geographic localities, and the flesh of many pufferfish may not be dangerously toxic. The mechanism of toxicity is through the blockage of fast voltage-gated sodium channels, which are required for the normal transmission of signals between the body and brain. As a result, TTX causes loss of sensation, and paralysis of muscles including the diaphragm and intercostal muscles, stopping breathing.
Sources: en.wikipedia.org
codons, resulting in 2078 free parameters. However, the rates for transitions between codons which differ by more than one base are often assumed to be zero, reducing the number of free parameters to only
== Detecting proteins == In some applications, it is necessary to measure the total amount of protein present, rather than the levels of one particular protein. In these cases nonspecific protein assays can be used to quantitate the amount of protein in a sample. Common nonspecific protein assays include the Warburg–Christian method, Kjeldahl method, Lowry assay, and Bradford assay. Many of these rely on the spectrophotometric properties of proteins themselves or in complex with various dyes or reagents. For example, the Bradford Assay exploits the absorbance properties of Coomassie brilliant blue G-250 dye. When free of protein, the dye is red but once bound to protein it turns blue. The Kjeldahl method, in contrast, does not use any dye and is instead a titrimetric assay, sensitive to the nitrogen content in the sample, which correlates with protein content. These assays vary widely in sensitivity, specificity to proteins over other compounds in the sample, and cost.
== Research == Specific medications that may reduce the risk or progression of Alzheimer's disease include those that impact Aβ plaques, inflammation, APOE, neurotransmitter receptors, neurogenesis, growth factors or hormones. Machine learning algorithms with electronic health records are studied as a way to predict Alzheimer's disease earlier. As of 2025, 182 clinical trials were testing 138 drugs against multiple targets.
=== EC 1.2.2 With a cytochrome as acceptor === EC 1.2.2.1: formate dehydrogenase (cytochrome) EC 1.2.2.2: Now covered by EC 1.2.5.1, pyruvate dehydrogenase (quinone) EC 1.2.2.3: Now EC 1.17.2.3, formate dehydrogenase (cytochrome-c-553) EC 1.2.2.4: Now classified as EC 1.2.5.3, aerobic carbon monoxide dehydrogenase
Sources: en.wikipedia.org
=== Television specials === Television specials from part of the MCU are known as Special Presentations. The Marvel Studios Special Presentations Werewolf by Night and The Guardians of the Galaxy Holiday Special, both released in 2022, are part of Phase Four, and were followed by the Marvel Television Special Presentation The Punisher: One Last Kill (2026), which is part of Phase Six.
Oxilorphan (INN, USAN) (developmental code name L-BC-2605) is an opioid antagonist of the morphinan family that was never marketed. It acts as a μ-opioid receptor (MOR) antagonist but a κ-opioid receptor (KOR) partial agonist, and has similar effects to naloxone and around the same potency as an MOR antagonist. Oxilorphan has some weak partial agonist actions at the MOR (with miosis, nausea, dizziness, and some euphoria observed) and can produce hallucinogenic/dissociative effects at sufficient doses, indicative of KOR activation. It was trialed for the treatment of opioid addiction, but was not developed commercially. The KOR agonist effects of oxilorphan are associated with dysphoria, which combined with its hallucinogenic effects, serve to limit its clinical usefulness; indeed, many patients who experienced these side effects refused to take additional doses in clinical trials. It has been encountered as a novel designer drug.
== Bromine-77 == Bromine-77 is the most stable radioisotope of bromine, with a half-life of 57.04 hours. Although β+ decay is possible for this isotope, about 99.3% of decays are by electron capture. Despite its complex emission spectrum, featuring strong gamma-ray emissions at 239, 297, 521, and 579 keV, 77Br was used in SPECT imaging in the 1970s. However, except for longer-term tracing, this is no longer considered practical due to the difficult collimator requirements and the proximity of the 521 keV line to the 511 keV annihilation radiation related to the β+ decay. The Auger electrons emitted during decay are nevertheless well-suited for radiotherapy, and 77Br can possibly be paired with the imaging-suited 76Br (produced as an impurity in common synthesis routes) for this application.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.